Pathology: MIBC - NA - all population; mUC - L1 - all population; mUC - L2 - all population; mUC - L2 - PDL1 positive;
MIBC - NA - all population | mUC - L1 - all population | mUC - L2 - all population | mUC - L2 - PDL1 positive | ||||
IMvigor-010, 2021 | IMvigor-130 (At-arm B vs Ch-armC), 2020 | IMvigor-130 (At-arm A vs Pl-arm C), 2020 | IMvigor-211 (all population), 2018 | IMvigor-211 (PDL1>1%), 2018 | IMvigor-211 (PDL1>5%), 2018 | ||
atezolizumab alone | 5 | T1 | T1 | T1 | T1 | T1 | |
atezolizumab plus SoC | 1 | T1 | |||||
no additional treatment | 0 | T0 | |||||
gemcitabine plus platin | 0 | T0 | |||||
placebo plus SoC | 0 | T0 | |||||
Standard of Care (SoC) | 0 | T0 | T0 | T0 |